November 18th 2024
More than half of US adults—approximately 137 million—are candidates for semaglutide based on diabetes, weight management, or cardiovascular prevention indications.
November 16th 2024
Diabetes Drug's Cancer Risk Affirmed, FDA Says
Results of a 10-year study on bladder cancer risk with pioglitazone might be better than the five-year results led the US Food and Drug Administration to re-affirm that the danger is real--though slightly less than the preliminary data showed.
FDA Approves Combination Diabetes Drug Synjardy XR
Synjardy XR, a combination of empagliflozin and metformin hydrochloride, was approved this afternoon by the FDA for glucose management in type 2 diabetics. The drug is a collaboration between Boehringer Ingelheim Pharmaceuticals and Eli Lilly and Company.
Sitagliptin Safe Option in Diabetic Patients Admitted to Hospital?
Sitagliptin tablets proved more convenient and equally safe and effective as insulin injections in achieving glycemic control for people with diabetes admitted to hospitals for medical care or surgery, a five-center study found.